Candriam SCA’s Transmedics TMDX Stock Holding History

Candriam SCA’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.8M	Buy	158,766 +49,580	+45%	+$6.47M	0.08%	225
2025 Q4	$13.3M	Buy	+109,186	New	+$13.7M	0.07%	233

Other funds holding TMDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Candriam SCA's TMDX Position: Q1 2026 in Review

Candriam SCA increased its Transmedics (TMDX) stake by 45% in Q1 2026, buying an estimated $6.47M and bringing the position to 158,766 shares worth $15.8M. The position accounts for 0.08% of the portfolio, ranked #225.

Candriam SCA first reported a position in TMDX in Q4 2025 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

Candriam SCA held 158,766 shares of Transmedics worth $15.8M as of Q1 2026.
Candriam SCA bought 49,580 Transmedics shares in Q1 2026, an estimated $6.47M.
Transmedics made up 0.08% of Candriam SCA's portfolio in Q1 2026, its #225 holding.
Candriam SCA first reported a position in Transmedics in Q4 2025 and has held it in 2 quarters since.
414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.